2279.HK
Biokin does biopharma

Hair transplant specialist Yonghe Medical Group Co. Ltd. (2279.HK) said on Tuesday it expects its net loss for 2024 to narrow significantly to 246 million yuan ($33.73 million) or less, down 55% from a 547 million yuan loss in 2023.

The company credited the improvement primarily to optimization of its store network, including the closure of underperforming outlets to focus on its best locations, leading to a substantial improvement in operational efficiency. Implementation of the company’s self-developed Hefan medical management system also enabled refined multi-process management, helping to boost its 2024 gross profit by 7% to 10% and gross profit margin by 3 percentage points to 5 percentage points compared to 2023.

Additionally, the company’s cost control measures, including adjustments to its marketing strategy and workforce optimization, led to year-on-year decreases of 8% to 9% in the ratio of sales and marketing expenses to total revenue, and 5% to 6% in the general and administrative expense ratio.

Yonghe Medical’s stock fell in the morning session on Tuesday, closing at HKD1 by midday break, down 2.9%.

By Lee Shih Ta

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

Zepp makes wearable products

Zepp hits its stride with return to revenue growth

The maker of low-end wearable devices reported its revenue rose 78.5% in the third quarter, but forecast the rate would ease to about 40% in the current quarter Key Takeaways:…
Man Wah subsidiary Remacro NEEQ listing

Man Wah sets spin-off in motion for its sofa tech unit

The Chinese furniture giant is preparing to list its components subsidiary Remacro to raise the technology unit’s profile and open an independent funding channel Key Takeaways: After listing on China’s…